- Report
- April 2024
- 293 Pages
Global
From €5303EUR$5,450USD£4,543GBP
- Report
- August 2023
- 500 Pages
Global
From €9243EUR$9,500USD£7,918GBP
- Report
- April 2023
- 99 Pages
Europe
From €1459EUR$1,500USD£1,250GBP
- Report
- January 2023
- 110 Pages
Global
From €4622EUR$4,750USD£3,959GBP
- Report
- March 2019
- 746 Pages
Global
€21406EUR$22,000USD£18,337GBP
- Report
- August 2018
- 31 Pages
Global
From €9730EUR$10,000USD£8,335GBP
- Report
- August 2018
- 20 Pages
Global
From €9730EUR$10,000USD£8,335GBP
- Report
- April 2018
- 196 Pages
Global
From €21406EUR$22,000USD£18,337GBP
- Report
- March 2019
- 164 Pages
Global
From €10698EUR$10,995USD£9,164GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €486EUR$500USD£417GBP
- Report
- January 2019
- 35 Pages
Global
From €973EUR$1,000USD£834GBP
- Report
- February 2024
- 72 Pages
Global
From €3500EUR$3,853USD£3,103GBP
Velcade (bortezomib) is a chemotherapy drug used to treat multiple myeloma and mantle cell lymphoma, two types of blood cancer. It is a proteasome inhibitor, meaning it works by blocking the action of proteasomes, which are responsible for breaking down proteins in cells. Velcade is administered intravenously or subcutaneously, and is often used in combination with other drugs. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma and mantle cell lymphoma.
Velcade is one of several drugs used to treat leukemia, a type of cancer that affects the blood and bone marrow. Other drugs used to treat leukemia include chemotherapy, targeted therapy, and immunotherapy. The choice of treatment depends on the type of leukemia and the patient's overall health.
Velcade is marketed by Takeda Pharmaceuticals, Janssen Biotech, and Millennium Pharmaceuticals. Other companies in the market include Celgene, Novartis, and Pfizer. Show Less Read more
